2019
DOI: 10.1136/bmjopen-2018-028783
|View full text |Cite
|
Sign up to set email alerts
|

Ward-based Goal-Directed Fluid Therapy (GDFT) in Acute Pancreatitis (GAP) trial: study protocol for a feasibility randomised controlled trial

Abstract: IntroductionAcute pancreatitis is an inflammatory disease of the pancreas with high risk of developing multiorgan failure and death. There are no effective pharmacological interventions used in current clinical practice. Maintaining fluid and electrolyte balance is the mainstay of supportive management. Goal-directed fluid therapy (GDFT) has been shown to decrease morbidity and mortality in surgical conditions with systemic inflammatory response. There is currently no randomised controlled trial (RCT) investig… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 25 publications
0
5
0
Order By: Relevance
“…A detailed protocol of the GAP trial has been published [ 10 ]. In summary, it was designed as a two-centre, feasibility randomised controlled trial.…”
Section: Methodsmentioning
confidence: 99%
“…A detailed protocol of the GAP trial has been published [ 10 ]. In summary, it was designed as a two-centre, feasibility randomised controlled trial.…”
Section: Methodsmentioning
confidence: 99%
“…The clinical trial was conducted according to the previously published protocol (11). Adult patients (age 18 to 80 years) with a diagnosis of liver cirrhosis listed for LT at the Royal Free London NHS Foundation Hospital Trust, were invited to participate in the trial.…”
Section: Study Setting and Patientsmentioning
confidence: 99%
“…A detailed protocol of the GAP trial has been published (Froghi et al, 2019). In summary, it was designed as a two-centre, feasibility randomised controlled trial.…”
Section: Trial Design and Deliverymentioning
confidence: 99%